Wipro has collaborated with 4baseCare to develop precision oncology solutions that will improve the affordability and timely availability of gene testing reports for cancer patients. 4baseCare and Wipro will jointly pave the way for cancer patients to gain access to advanced genomic testing at an affordable cost and reduce the turnaround time (TAT) on test results to almost half from current market average of 30 days.
The partners will build a framework of efficient, streamlined, and well-regulated workflows for the development of advanced gene panels. Through this partnership, oncologists, cancer hospitals, and cancer clinics can tap diagnostics and prognostics cancer gene panels at an economical price point. It can help them identify and understand the genetic mutation of cancer, and design treatments to specifically target these mutations.
Wipro is a leading global information technology, consulting and business process services company.
| Company Name | CMP |
|---|---|
| TCS | 2392.45 |
| Infosys | 1176.80 |
| HCL Tech. | 1194.95 |
| Wipro | 196.60 |
| Tech Mahindra | 1457.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: